Crescent Biopharma, Inc.CBIONASDAQ

|||

Overview Charts News Fundamentals Key Metrics TTM Financials Earnings Growth Rating Analysts Institutional Peers Historical

Analyst Sentiment

Analysts lean bullish — 69% recommend buying.

Consensus Rating

Buy

13 analysts·Moderate coverage

69%

Rating Distribution

Strong Buy

00%

Buy

969%

Hold

431%

Sell

00%

Strong Sell

00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Analysts see significant upside — consensus target 216% higher.

Bear Case

$26.00

+156%

Consensus

$32.00

+216%

Bull Case

$35.00

+245%

Price Range13 analysts

Low

Consensus

High

$26.00

$35.00

Current Target

Current Price

$10.14

Upside to Target

$21.86

Price targets are 12-month forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

2026E$-5.34(5 analysts)

Actual

Estimate

Range (Low–High)

Stock Alarm Pro

Forward Growth Estimates (YoY)

FY2027

Rev+56.67%

EPS—

FY2028

Rev+59.57%

EPS—

FY2029

Rev+268.38%

EPS—

Earnings Surprises

Beat rate:42%(5/12 quarters)

Avg surprise:-6.0%

Beat

Miss

Inline

Estimate

Based on reported EPS vs consensus estimate.

Recent Analyst Actions

Jan 28, 2026Piper Sandler

Crescent Biopharma initiated with an Overweight at Piper Sandler

Target:$35.00

+210.6%from $11.27

Jan 21, 2026Guggenheim

Crescent Biopharma initiated with a Buy at Guggenheim

Target:$35.00

+150.4%from $13.98

Dec 4, 2025Stifel Nicolaus

Crescent Biopharma price target raised to $32 from $28 at Stifel

Target:$32.00

+146.3%from $12.99

Aug 25, 2025Jefferies

Crescent Biopharma initiated with a Buy at Jefferies

Target:$26.00

+76.9%from $14.70

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance